Shilpa Medicare Limited

NSEI:SHILPAMED Stock Report

Market Cap: ₹73.2b

Shilpa Medicare Past Earnings Performance

Past criteria checks 2/6

Shilpa Medicare's earnings have been declining at an average annual rate of -47.2%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 6.5% per year. Shilpa Medicare's return on equity is 2.6%, and it has net margins of 5%.

Key information

-47.2%

Earnings growth rate

-48.5%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate6.5%
Return on equity2.6%
Net Margin5.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Reasonably Well

Jan 02
These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Reasonably Well

What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Sep 12
What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

Jul 05
Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Apr 12
What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Feb 21
Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

Jan 02
Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Jul 17
These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Mar 17
Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Sep 22
Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Sep 07
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Aug 14
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Jan 27
Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Sep 21
Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jun 17
Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

May 31
If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 07
Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Feb 20
Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Revenue & Expenses Breakdown

How Shilpa Medicare makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:SHILPAMED Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2412,1636113,0480
30 Jun 2411,8394482,8080
31 Mar 2411,5313193,0250
31 Dec 2311,248-72,9780
30 Sep 2311,008-1192,9730
30 Jun 2310,491-3212,8730
31 Mar 2310,517-3252,9690
31 Dec 2211,286513,0630
30 Sep 2211,3842133,0540
30 Jun 2211,6935992,7950
31 Mar 2211,4696072,8240
31 Dec 2110,1353952,6920
30 Sep 219,3243762,6120
30 Jun 219,1566312,4040
31 Mar 219,0161,4782,4730
31 Dec 209,1351,7392,2810
30 Sep 209,5912,2132,1680
30 Jun 209,6982,2672,0270
31 Mar 209,0821,5622,0430
31 Dec 198,8761,4552,0220
30 Sep 198,2411,0291,9830
30 Jun 196,9629441,8260
31 Mar 197,3371,1231,8340
31 Dec 187,6931,1931,7760
30 Sep 187,8141,2811,7040
30 Jun 188,2111,1671,5660
31 Mar 187,8941,0521,5550
31 Dec 177,7561,1331,4980
30 Sep 177,7311,1491,4220
30 Jun 177,7871,1901,3190
31 Mar 177,7951,0761,3300
31 Dec 167,5651,0481,1580
30 Sep 167,7351,1531,0920
30 Jun 167,3691,0241,0070
31 Mar 167,1661,0839340
31 Dec 156,8678861,170159
30 Sep 156,4307761,113159
30 Jun 156,2347288440
31 Mar 156,1387378550
31 Dec 146,14573199795
30 Sep 146,14379899195
30 Jun 145,9667877230
31 Mar 145,71475791395

Quality Earnings: SHILPAMED has high quality earnings.

Growing Profit Margin: SHILPAMED became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SHILPAMED's earnings have declined by 47.2% per year over the past 5 years.

Accelerating Growth: SHILPAMED has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SHILPAMED has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).

Return on Equity

High ROE: SHILPAMED's Return on Equity (2.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 19:56
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shilpa Medicare Limited is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAntique Stockbroking Ltd.
Harith AhamedAvendus Spark
Prathamesh MasdekarBP Wealth Management Private Limited